肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2013年
9期
609-611
,共3页
骆梅青%卜庆%曹轶林%郑桂银%伍爱华%施朕善
駱梅青%蔔慶%曹軼林%鄭桂銀%伍愛華%施朕善
락매청%복경%조질림%정계은%오애화%시짐선
癌,非小细胞肺%Nanog%药物疗法,联合%治疗结果
癌,非小細胞肺%Nanog%藥物療法,聯閤%治療結果
암,비소세포폐%Nanog%약물요법,연합%치료결과
Cancer,non-small cell lung%Nanog%Drug therapy,combination%Trentment outcome
目的 探讨中晚期(Ⅲ期和Ⅳ期)非小细胞肺癌(NSCLC)患者Nanog基因和蛋白的表达与GP方案化疗的疗效关系,并分析对生存期的影响.方法 选择使用GP方案化疗的晚期NSCLC患者62例,对使用实时定量聚合酶链反应(qRT-PCR)和免疫组织化学两种方法均检测出Nanog阳性表达的肺癌患者进行GP方案治疗的效果进行对比,并对生存期的影响进行统计分析.结果 62例中晚期NSCLC中,Nanog基因和蛋白表达呈阳性30例(48.4％),Nanog阳性表达患者的有效率与未表达的患者比较差异有统计学意义(x2=10.872,P＜0.01).完全缓解(CR)组的Nanog阳性表达明显低于部分缓解(PR)组和进展(PD)组,32例有效(CR+PR)患者中Nanog呈阳性表达9例(28.1％),阴性表达23例(71.9％).而未显效的32例中Nanog呈阳性表达21例(70.0％),阴性表达9例(30.0％).生存分析显示,Nanog阳性表达的患者5年生存期短于Nanog阴性表达的患者.结论 Nanog表达增强可能导致NSCLC患者对GP方案化疗不敏感并导致5年生存期缩短,检测Nanog的表达可为临床制定NSCLC的个体化治疗方案提供依据,并对预测肿瘤的预后提供参考.
目的 探討中晚期(Ⅲ期和Ⅳ期)非小細胞肺癌(NSCLC)患者Nanog基因和蛋白的錶達與GP方案化療的療效關繫,併分析對生存期的影響.方法 選擇使用GP方案化療的晚期NSCLC患者62例,對使用實時定量聚閤酶鏈反應(qRT-PCR)和免疫組織化學兩種方法均檢測齣Nanog暘性錶達的肺癌患者進行GP方案治療的效果進行對比,併對生存期的影響進行統計分析.結果 62例中晚期NSCLC中,Nanog基因和蛋白錶達呈暘性30例(48.4％),Nanog暘性錶達患者的有效率與未錶達的患者比較差異有統計學意義(x2=10.872,P＜0.01).完全緩解(CR)組的Nanog暘性錶達明顯低于部分緩解(PR)組和進展(PD)組,32例有效(CR+PR)患者中Nanog呈暘性錶達9例(28.1％),陰性錶達23例(71.9％).而未顯效的32例中Nanog呈暘性錶達21例(70.0％),陰性錶達9例(30.0％).生存分析顯示,Nanog暘性錶達的患者5年生存期短于Nanog陰性錶達的患者.結論 Nanog錶達增彊可能導緻NSCLC患者對GP方案化療不敏感併導緻5年生存期縮短,檢測Nanog的錶達可為臨床製定NSCLC的箇體化治療方案提供依據,併對預測腫瘤的預後提供參攷.
목적 탐토중만기(Ⅲ기화Ⅳ기)비소세포폐암(NSCLC)환자Nanog기인화단백적표체여GP방안화료적료효관계,병분석대생존기적영향.방법 선택사용GP방안화료적만기NSCLC환자62례,대사용실시정량취합매련반응(qRT-PCR)화면역조직화학량충방법균검측출Nanog양성표체적폐암환자진행GP방안치료적효과진행대비,병대생존기적영향진행통계분석.결과 62례중만기NSCLC중,Nanog기인화단백표체정양성30례(48.4％),Nanog양성표체환자적유효솔여미표체적환자비교차이유통계학의의(x2=10.872,P＜0.01).완전완해(CR)조적Nanog양성표체명현저우부분완해(PR)조화진전(PD)조,32례유효(CR+PR)환자중Nanog정양성표체9례(28.1％),음성표체23례(71.9％).이미현효적32례중Nanog정양성표체21례(70.0％),음성표체9례(30.0％).생존분석현시,Nanog양성표체적환자5년생존기단우Nanog음성표체적환자.결론 Nanog표체증강가능도치NSCLC환자대GP방안화료불민감병도치5년생존기축단,검측Nanog적표체가위림상제정NSCLC적개체화치료방안제공의거,병대예측종류적예후제공삼고.
Objective To evaluate the correlation between the expression level of Nanog gene and clinical outcomes of GP regimen in the advanced non-small cell lung cancer (NSCLC).Methods 62 patients of NSCLC were treated by GP method,and the outcomes were investiged between Nanog positive and nagetive patients.The expression level of Nanong was evaluated by RT-PCR and immunohistology.Results 30 out of 62 patients (48.4 ％) were Nanog positive,9 patients (28.1％) were Nanog positive,and 23 out of 32 patients were Nanog negative (71.9 ％) who have the positive effect (CR+PR).However,among 32 treatment nagetive cases,there were 21 cases (70.0 ％) who were Nanog positive and 9 cases (30.0 ％) were Nanog negatve.Survival analysis showed that 5-years lifetime of Nanog positive patients was shorter than Nanong nagetive patients.Conclusion Nanog overexpression decreases the sensitivity of GP regimen and lifetime of NSCLC patient.Nanog expression level may provide a useful factor for clinical treatment and prognosis of NSCLC patient.
